Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.


Clinical Trial Description

This is a randomized, double-blind, placebo-controlled, multicenter phase III study. The study population will consist of approximately 1300 subjects with metastatic hormone sensitive prostate cancer (mHSPC), who will be randomized (1:1 ratio) to receive 600 mg (2 x 300 mg tablets) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total daily dose of 1200 mg, in addition to standard androgen deprivation therapy (ADT) and docetaxel. Subjects will be stratified at randomization for the extent of disease and for Alkaline Phosphatase levels. All subjects will be treated with ADT as standard therapy. Six cycles of docetaxel will be administered after randomization. The subjects considered for inclusion in the study will have metastatic prostate cancer and will be candidates for ADT and docetaxel. Treatment with darolutamide (ODM-201)/placebo will be administered until symptomatic progressive disease, change of antineoplastic therapy, unacceptable toxicity, until subject withdraws consent, withdrawal from the study at the discretion of the investigator or his/her designated associate(s), death, non-compliance, or if sponsor terminates the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02799602
Study type Interventional
Source Bayer
Contact
Status Completed
Phase Phase 3
Start date November 30, 2016
Completion date April 11, 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06334120 - An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Completed NCT05381311 - Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Active, not recruiting NCT00309985 - Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Phase 3
Completed NCT03532217 - Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Phase 1
Active, not recruiting NCT05059236 - A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Phase 2
Not yet recruiting NCT06134271 - Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer Phase 2
Active, not recruiting NCT04934722 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Phase 3
Recruiting NCT05901649 - A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Not yet recruiting NCT06452212 - Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients
Withdrawn NCT03343977 - Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase 1/Phase 2
Active, not recruiting NCT04191096 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Phase 3
Active, not recruiting NCT03879122 - A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer Phase 2/Phase 3